Featured Articles
Roche acquisition of Spark Therapeutics continues to build gene therapy market
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) recently announced the completion of the acquisition of the gene therapy company, following regulatory approval from government authorities. Roche’s $4.8 billion acquisition of Spark was a 64% increase from its initial $2.7 billion offer in what turned out to be a two-way […]
Read full storyRetinal clinical trials indicate that almost 50% of studies have non-compliance issues
Clinical research has indicated that almost half of trial studies have noncompliance issues, creating negative impact outcomes for research. A recent study has shown that 54.4% of patients were compliant with completing all study visits while 45.6% of subjects were noncompliant. Given that trials are a cornerstone to collect patient data in order to build […]
Read full storyStrategy aims to overcome RP heterogeneity using gene therapy treatment with dominant retinitis pigmentosa
Researchers at the Scheie Eye Institute, University of Pennsylvania, has reported that a mutation-independent strategy for treating autosomal dominant retinitis pigmentosa (adRP) prevents photoreceptor cell death in the retina. The research team developed a gene therapy approach using a single adeno-associated viral (AAV) system delivering the experimental treatment to a large animal model of RP. […]
Read full story